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ACRONYMS, ABBREVIATIONS  
BLIPS, Brief Limited Intermittent Psychotic Symptoms 
BIPS, Brief Intermittent Psychotic Symptoms 
ATPD, Acute and Transient Psychotic Disorder 
BPD, Brief Psychotic Disorder 
FES, First Episode Schizophrenia 
AT A GLANCE 
• The prognostic significance of competing operationalizations for brief psychotic 
episodes is unknown, leading to an untenable source of confusion for patients, carers, 
clinicians and researchers.  
• We presented a meta-analysis of the risk of psychotic recurrence over time in four 
diagnostic constructs of remitted first episode of brief psychosis, and in a benchmark 
group of remitted first episode schizophrenia. 
• No prognostic difference was found between different operationalizations of brief 
psychotic episodes at any follow-up timepoint. 
• In the longer term, risk of psychotic recurrence was significantly higher in remitted 
first episode schizophrenia compared with the four groups of brief psychotic 
episodes. 
• Current data should influence the diagnostic practice and clinical services in the 
management of early psychosis. 
ABSTRACT  
Importance 
The prognostic significance of competing constructs and operationalizations for brief 
psychotic episodes (Acute and Transient Psychotic Disorder, ATPD; Brief Psychotic 
Disorder, BPD; Brief Limited Intermittent Psychotic Symptoms, BLIPS; and Brief 
Intermittent Psychotic Symptoms, BIPS) is unknown. 
Objective 
To provide a meta-analytical prognosis of the risk of psychotic recurrence in remitted first-
episode ATPD, BPD, BIPS, and BLIPS and in a benchmark group of remitted first-episode 
schizophrenia (FES). We hypothesized a differential risk: FES>ATPD>BPD>BIPS>BLIPS.  
Data Sources  
Electronic databases were searched until 18th May 2015 along with investigation of citations 
of previous publications, and a manual search of the reference lists of retrieved articles.  
Study Selection 
We included original articles that reported the risk of psychotic recurrence at follow-up in 
remitted patients with first-episode ATPD, BPD, BLIPS, BIPS, and FES.  
Data Extraction and Synthesis 
Independent extraction by multiple observers. Random effect meta-analysis conducted with 
the “metaprop”,”metaninf”, “metafunnel”, “metabias” packages of STATA 13.1. Moderators 
were tested with meta-regression analyses, Bonferroni corrected. Heterogeneity was assessed 
with the I2 index. Sensitivity analyses tested robustness of results. Publication biases were 
assessed with funnel plots and Egger’s test. 
Main Outcome Measure 
Proportion of baseline ATPD, BPD, BLIPS, BIPS patients with any psychotic recurrence at 6, 
12, 24, and ≥36 months follow-up.  
Results 
Eighty-two independent studies comprising up to 11133 patients were included. There was no 
prognostic difference between ATPD, BPD, BLIPS, and BIPS at any follow-up (p>0.05). In 
the longer term, risk of psychotic recurrence was significantly higher in the FES group (from 
78% at 24 months to 84% at ≥36 months) compared with the other four groups (from 39% at 
6 months to 51% at ≥30 months). There were no publication biases; sensitivity analyses 
confirmed robustness of results. Exposure to antipsychotic and gender modulated the meta-
analytical estimates (uncorrected threshold).  
Conclusions and Relevance 
There are no prognostic differences between ATPD, BPD, BLIPS and BIPS. Conversely, 
there is consistent meta-analytical evidence for a better long-term prognosis of brief acute 
psychoses compared with remitted schizophrenia. These findings should influence the 
diagnostic practice and clinical services in the management of early psychosis.  
Keywords: Psychosis, Brief, Acute, Schizophrenia, CAARMS, SIPS, ICD, DSM 
“The nomenclature of these acute disorders is as uncertain as their nosological status. […] 
Systematic clinical information that would provide definitive guidance on the classification of 
acute psychotic disorders is not yet available, and the limited data and clinical tradition that 
must therefore be used instead do not give rise to concepts that can be clearly defined and 
separated from each other”. 
World Health Organization (WHO)1 
INTRODUCTION 
As psychotic disorders of “dramatic symptomatology”2 but remitting course, brief psychotic 
episodes represent one of the most intriguing paradoxes in psychiatry. Kahlbaum (1828-1899) 
first distinguished the typical progressive nature of psychotic forms (“vesania typica”) from a 
separate group of disorders (“dysphrenia”) that appeared in an acute and severe form, but then 
remitted with a full recovery “without leaving a lasting alteration in the elements that serve its 
expression (1863 page 67)3”. Kahlbaum’s classification did not catch on. Instead, the 
nosography of Kraepelin (1856–1926) dominated psychiatry and shaped today’s diagnostic 
system.2 Brief and acute psychoses have been difficult to accommodate as a “third psychosis” 
in the Kraepelinian dichotomy of dementia praecox and manic-depressive insanity.4 They 
have been repeatedly reconceptualised and operationalized without finding a widely agreed 
nosographic cataloguing either as “bouffée délirante des dégénérés”,5 “cycloid psychoses”,6 
“reactive psychoses”,7 “emotional psychoses”,8 “atypical psychoses”,9 or “schizophreniform 
state”10 (see Figure 1 for more historical details).  
 
[FIGURE 1]  
 
The nosographic nomadism of brief psychotic episodes continues today. The WHO 
has brought the above clinical concepts into the ICD diagnostic category of Acute and 
Transient Psychotic Disorders (ATPD, with six subtypes), a short and remitting episode of 
psychosis which may last up to three months.1 Similarly, the American Psychiatric 
Association has introduced in the DSM the notion of Brief Psychotic Disorder (BPD), 
describing the psychosis whose duration is less than a month with full recovery to the 
premorbid status.11 Although ATPD and BPD address similar constructs, major 
operationalization differences exist in terms of their symptomatic features, symptom duration 
(3 months in ATPD vs. 1 month in BPD) and subtypes (schizophreniform-like disorders are 
included in ATPD) (Table 1). Previous investigations tend to suggest that patients with ATPD 
and BPD may fare better overall than patients with schizophrenia12, but the recurrence of 
subsequent psychotic episodes in ATPD and BPD may be as frequent as in schizophrenia.13 
This literature has not been subject to meta-analysis until now. The current meta-analytical 
approach is of particular relevance given that operationalization differences may affect their 
prognostic concordance,14 and the diagnostic stability of brief psychosis is questionable.15  
 
[TABLE 1] 
 
One further complication is that over the past two decades, brief psychotic episodes 
have been reclassified into pre-psychotic at risk states,16 as operationalized with the Brief and 
Limited Intermittent Psychotic Symptoms (BLIPS) concept:17 “young people with a history of 
fleeting psychotic experiences that spontaneously resolved within one week”, without the use 
of antipsychotics.18 Such a decision was based on the speculation that the BLIPS are the 
"psychosis equivalent" of transient ischemic attacks (TIAs) observed in neurology: sudden 
neurological abnormalities resembling a full stroke but settling down within 24 hours, with 
complete clinical recovery19 and a limited risk of stroke.20 A few years later, the duration of 
Brief Intermittent Psychotic Symptoms (BIPS) was extended from 7 days to 3 months by 
other authors (Table 1).21 Although converging studies (Fig 3 in22), consensus reviews16 and a 
recent meta-analysis23 have demonstrated the clinical distinctiveness between BLIPS/BIPS 
and the other two high risk subgroups of attenuated psychosis syndrome and genetic risk and 
deterioration syndrome,16 the actual prognostic significance in BLIPS and BIPS, and their 
validity as the at-risk state as opposed to frank psychosis (as for ATPD/BPD) is unclear.24 
Because of this, the presence of the four competing diagnostic constructs (ATPD, BPD, 
BLIPS and BIPS) is a major source of “Babylonian confusion,25 offering little to guide 
prognosis or treatment and representing an untenable challenge for patients, carers, clinicians 
and researchers. Paradoxically, depending on the local availability of high risk services, 
young adults presenting with brief psychotic episodes features may either receive a diagnosis 
of established psychosis and antipsychotic treatment (as ATPD/BPD),26 or an at-risk 
diagnosis (as BLIPS/BIPS)27 and undergo the recommended psychological interventions.28 
Prognostic uncertainty is also a major source of heterogeneity undermining research and 
hindering the discovery of reliable biomarkers to be used in the clinic.29  
 
This is the first large-scale meta-analysis primarily testing the differential prognostic 
significance (predictive validator)30 of remitted first-episode ATPD, BPD, BLIPS, and BIPS. 
Second, we choose to compare them with remitted first-episode schizophrenia (FES) to 
provide a clinical “benchmark”. On the basis of spontaneous remission without antipsychotics 
treatment (in BLIPS/BIPS) and symptoms duration (up to 7 days for BLIPS, less than 4 
days/week over 3 months for BIPS, up to 1 continuous month for BPD, and up to 3 
continuous months for ATPD), our primary hypothesis was that the risk of a subsequent 
psychotic recurrence progressively increased across these four competing constructs 
(BLIPS<BIPS<BPD<ATPD). The secondary hypothesis was that this risk was higher in the 
benchmark group of remitted FES.  
 
METHODS 
Search strategy 
Three investigators (MC, GR, CH) conducted two-step literature searches. First, the Web of 
KnowledgeSM database was searched, incorporating both the Web of ScienceSM and 
MEDLINE®. The search was extended until 18th May 2015, including abstracts in English 
language only. The electronic research adopted several combinations of the following 
keywords: “ATPD”, “BPD”, “BLIPS”, “BIPS”, “ICD”, “DSM”, “psychosis risk”, “first 
episode psychosis”, “first episode schizophrenia”, “diagnostic stability”, “remission” and 
“relapse”. Second, we used Scopus® to investigate citations of possible previous 
reviews/meta-analyses on development of another episode of psychosis from an initial first 
brief psychotic episode, and a manual search of the reference lists of retrieved articles. 
Articles identified through these two steps were then screened for the selection criteria on 
basis of abstract reading. The articles surviving this selection were assessed for eligibility on 
basis of full-text reading, following the MOOSE checklist (eTable1).31 
 
Selection criteria 
Studies were eligible for inclusion if the following criteria were fulfilled: (a) original articles 
in English; (b) included a baseline group of patients diagnosed with remitted first-episode 
brief psychoses, as defined according to standard international classification (ATPD, BPD)1, 11 
or according to the high risk paradigm (BLIPS, BIPS),32-34 or a comparison benchmark group 
of remitted FES1, 11 (see (d)); (c) reported the risk of psychotic recurrence at follow-up. 
ATPD, BPD, BLIPS and BIPS are per definition brief and remitting. BLIPS/BIPS are 
antipsychotic naïve or minimally treated, while ATPD/BPD have a favourable response to 
antipsychotics35 and they are often (76%36) antipsychotic free at follow-up, so that 
maintenance medication is used less often than schizophrenia.12 Accordingly, to minimize the 
potential confounding effect of illness chronicity and prolonged antipsychotic treatments, 
FES studies were included if they (d) had investigated remitted first-episode patients (as 
defined in eTable 2b). When data were not directly presented they were indirectly extracted 
from associated data or corresponding authors were contacted to retrieve additional data. 
Exclusion criteria were: (a) abstracts, pilot datasets, and paper in languages other than 
English; (b) articles that were not employing the internationally validated diagnoses for 
ATPD, BPD, BLIPS, BIPS, and FES; (c) articles with overlapping datasets; (d) high risk 
samples belonging to the genetic risk and deterioration syndrome and the attenuated 
psychosis symptoms subgroups; (e) FES studies with samples who had not fully remitted 
from their first episode; and (f) studies with samples of multi-episode or chronic psychosis. 
Specifically, in case of multiple publications deriving from the same study population, we 
selected the articles reporting the largest and most recent data set. Literature search was 
summarized according to the PRISMA guidelines.37 
 
Recorded variables 
Data extraction was independently performed by two investigators (MC, GR). To estimate the 
primary outcome variable we extracted the baseline sample size and the number of patients 
with any psychotic disorders at follow-up. To estimate the secondary outcome we 
additionally collected the number of patients who developed into schizophrenia or affective 
psychoses at follow-up. We collected additional moderators as indicated in the statistical 
analysis and performed quality assessment as detailed in eMethods 1. 
 
Statistical analysis 
The outcome measure was the risk of psychotic recurrence in patients who have been remitted 
from their first episode of ATPD, BPD, BLIPS, BIPS (primary outcome), and FES 
(secondary outcome). This was calculated as the proportion of baseline patients who had any 
psychotic recurrence at 6, 12, 24 or more than 36 months follow-up. Meta-analysis was 
conducted with the “metaprop” package38 of STATA 13.1. This package is specifically 
developed for pooling proportions in a meta-analysis of multiple studies. The confidence 
intervals are based on score(Wilson) or exact binomial(Clopper-Pearson) procedures.39 
Metaprop first transforms proportions with the Freeman-Tukey Double Arcsine 
Transformation40 to stabilize the variances and then performs a random effect meta-analysis 
implementing the Der Simonian-Laird method.41 The influence of moderators was tested 
using subgroup (type of antipsychotic treatment, study design, remission criteria in FES 
groups) and meta-regression (publication year, mean age, proportion of females, exposure to 
antipsychotics from baseline to follow-up, diagnostic criteria used to assess the psychotic 
episodes at follow-up, quality assessment) analyses. The slope of meta-regression line (β-
coefficient: direct (+) or inverse (-)) indicates the strength of a relationship between 
moderator and outcome. The meta-regressions were Bonferroni corrected for multiple testing. 
Heterogeneity among study point estimates was assessed using Q statistics with the 
proportion of the total variability in the effect size estimates being evaluated with the I2 
index,42 which does not depend upon the number of studies included. As meta-analysis of 
observational studies is supposed to be characterized by significant heterogeneity, random 
effect models were used. Additionally, sensitivity analyses were conducted to investigate the 
influence of each single study on the overall risk estimate by omitting one study at a time, 
using STATA’s user-written function namely “metainf”.43, 44 A study was considered to be 
influential if the pooled mean estimate without it was not within the 95% confidence bounds 
of the overall mean. Publication biases were assessed with the “metafunnel” function of 
STATA which produced funnel plots for assessing small-study reporting bias in meta-
analysis45 and with the Egger’s test46 in “metabias”47 function of STATA. Supplementary 
analyses are detailed in eMethods 2.  
 
RESULTS 
Database 
Literature search (PRISMA flow-chart eFigure 1) uncovered 82 independent articles, where 
some contributed with more than one sample. We identified a total of 93 independent 
samples: 27 ATPD, 22 BPD, 13 BLIPS, 10 BIPS, and 21 FES. Age, gender, diagnostic 
instrument employed to assign the baseline and the follow-up diagnosis, duration of follow-
up and exposure to antipsychotics for each included sample are detailed in eTable 2a and 
eTable 2b.  
 
Meta-analytical prognosis of brief psychotic episodes 
The 93 independent samples reported primary outcome data at different follow-up timepoints 
(Table 2).  
 
[TABLE 2] 
 
There was significant between-group heterogeneity across all timepoints (p<0.001). 
Across all timepoints, no significant differences were found in the risk of psychotic 
recurrence between ATPD, BPD, BLIPS and BIPS (Figure 2 & Table 2).  
 
[FIGURE 2] 
 
Comparison with remitted schizophrenia 
We found significantly higher risk of psychotic recurrence in the FES group as compared 
with the other four groups, at and after 24 months. Subgroup analyses in eFigures 2a-c had 
identified a modulating effect of antipsychotic treatment in the short term (i.e at 6 and 12 
months), but no effect for remission criteria and study design. 
 
Meta-regressions, publication biases, and sensitivity analyses 
Meta-regressions investigating year of publication, mean age, proportion of females, exposure 
to antipsychotics from baseline to follow-up, diagnostic criteria used to assess the psychotic 
episode at follow-up, and quality assessment are appended in eTable 4. At uncorrected 
threshold for multiple comparisons there was a significant effect for gender (12 and 24 
months) and antipsychotic exposure (6, 12, 24 months). Sensitivity analyses were described 
in eResults 1 and confirmed robustness of the findings. There was no evidence of publication 
biases as indicated by visual inspections of the funnel plots (eFigure 3a-c) and by the Egger’s 
test for small study effects (at all timepoints p>0.05). 
 
Supplementary analyses  
No meta-analytical differences in the risk of developing into schizophrenia at 24 months were 
observed within the ATPD, BPD, BLIPS, and BIPS groups (eFigure 4a and b). No meta-
analytical differences in the risk of developing into affective psychoses were detected within 
the ATPD, BPD, BLIPS, BIPS and FES groups (eFigure 5). The diagnostic stability and 
diagnostic change of each category, given psychotic recurrence occurs at follow-up, is 
detailed in eTable 5.  
 
DISCUSSION 
Although brief, the intensity and polymorphism of brief psychotic episodes present a clinical 
challenge. To address this, we report the first meta-analytical review of prognosis from a 
large dataset comprised of 82 studies with up to 11133 patients with remitted first-episode 
ATPD, BPD, BLIPS, and BIPS compared with remitted FES patients. Contrary to our 
primary hypothesis, there was no prognostic difference between patients with ATPD, BPD, 
BLIPS, BIPS in all timepoints. In line with our secondary hypothesis, the risk of psychotic 
recurrence in the long term (at 24 and ≥36 months) was significantly higher in the FES group 
compared with the other four groups. 
 
This novel study has provided combined robust meta-analytical evidence from 11133 
patients with first-episode psychotic disorders, in contrast to single studies, where sample size 
of brief psychotic episodes is relatively small. Our primary findings of no meta-analytical 
prognostic differences in the risk of psychotic recurrence between ATPD and BPD are in line 
with original data indicating a good concordance between the two constructs, further 
supporting the claim that there is no “clinical, practical, theoretical reason to separate them” 
(page 1548). An earlier study in 42 ATPD patients found that 62% also fulfilled the BPD 
criteria.14 A follow-up study in 343 first hospitalized patients showed that 29% were 
diagnosed with ATPD and 25% with BPD, for an overall kappa score of 0.71.49 Other studies 
conducted in 50050 and 40351 first-episode patients confirmed similar 2 years50 and 10 years51 
prospective consistency across ATPD and BPD. Despite this, some notable differences 
between DSM and ICD are still present. For example, our supplementary analysis restricted 
to cases who had a psychotic recurrence (eTable 5) showed some between-group differences 
which were driven by higher risk of recurrent brief psychotic episodes (relapses) in the ATPD 
(cycloid psychoses6) group, and by the fact that schizophreniform features are coded within 
the ATPD (subtype acute schizophrenia-like psychotic disorder), while they are coded as an 
independent schizophreniform disorder in the DSM. These controversies will be addressed by 
the diagnostic revision planned in the next ICD-11 manual,15 where only the subtype 
polymorphic psychotic disorder without symptoms of schizophrenia (F23.0) will be retained 
as ATPD (see eDiscussion 1).  
 
The absence of a meta-analytical prognostic difference between BLIPS and BIPS 
calls into question the strict 7 days duration in BLIPS. On one hand, the psychosis threshold 
is higher in the BIPS than in the BLIPS (psychotic symptoms may last for more than 7 days to 
3 months); but, on the other hand, it is lower since the BIPS symptoms should not have 
urgency features52 (“urgency is any positive psychotic symptom that is seriously 
disorganizing or dangerous no matter what the duration”, page 15).53 These two differences 
may counterbalance each other, and hence explain their comparable risks of psychotic 
recurrence over time and further suggest a need for some psychometric standardization across 
the two competing definitions.54 
 
Additionally, our meta-analysis suggests that the BLIPS/BIPS are prognostically 
overlapping with the ATPD/BPD (Table 2), which challenges both the validity of the 
BLIPS/BIPS as a high risk state for psychosis onset and the arbitrary use55 of psychosis 
severity thresholds in this field.52 The overlap is confirmed by our supplementary analysis 
showing a similar risk of developing into schizophrenia in BLIPS/BIPS (21%) and in 
ATPD/BPD (15%) by 24 months (eFigure 4b). The speed of progression to psychotic 
recurrence is also similar, with a mean time to diagnosis of less than 2 years for both 
BLIPS/BIPS56 and ATPD57/BPD. Although the authors of the BIPS acknowledged that 
“patients whose fully psychotic experience is of sufficient short duration to meet DSM 
criteria for brief psychotic disorder could potentially meet prodromal criteria”,58 this is the 
first convincing evidence supporting this notion. Our prognostic overlap is further 
corroborated by converging evidence indicating that BLIPS/BIPS present distinctive 
diagnostic,24 psychopathological,16 prognostic59, 60 and therapeutic needs61 when compared 
with the other high risk groups (for details see62). The level of risk of BLIPS/BIPS is 
comparable to ATPD/BPD and significantly higher23, 59 than attenuated psychosis symptoms 
and genetic risk and deterioration syndrome16.  Therefore, the mixture of BLIPS/BIPS and 
attenuated psychotic symptoms is unjustified as a homogeneous group expressing a pre-
psychotic risk state. Also, since indicated prevention63, 64 targets high risk people who do not 
meet the diagnostic criteria for a disorder65 (e.g. with attenuated psychosis symptoms), it is 
problematic that BLIPS/BIPS fall outside this framework, qualifying as prevention of 
psychotic recurrence65 (eDiscussion 2).  
 
One possible option would be to drop the BLIPS/BIPS entirely from the clinical high 
risk rubric. This would mirror the approach of excluding BLIPS/BIPS in the recent DSM-5 
Attenuated Psychosis Syndrome.66 However, adopting only the attenuated psychosis 
symptoms subgroups may cause a further significant drop in transition risks.67 Innovative 
strategies combining homogeneous high risk samples with attenuated psychotic symptoms 
only and neurodevelopmental deficits may yield a clinically significant risk enrichment (3-
years risk of psychosis of 28%).68 A more complex option would be to accept that the 
BLIPS/BIPS represents a distinct and separate high risk group23, which is prognostically 
overlapping with the ATPD/BPD, in the hope to harmonize the four competing constructs. 
This would better fit the notion of different levels of risk purported by the clinical staging 
model.69 However, it would also require redefining the psychotic threshold to be used in the 
high risk state accordingly. For instance, compromising on the one-month duration for 
psychotic symptoms would align the BLIPS/BIPS to that of ATPD in ICD-11 and BPD in 
DSM-5. Such a cross-diagnostic approach would fit with the DSM-5 which uses the level, the 
number, and the duration of psychotic signs and symptoms (reality distortion, negative 
symptoms, disorganization, cognitive impairments, motor symptoms, mood symptoms70) to 
demarcate psychotic disorders from each other,71 together with the new Clinician-Rated 
Dimensions of Psychosis Symptom Severity (C-RDPSS)72 scale. Given ATPD/BPD are 
relatively frequent, representing up to 6% of all first-episode psychoses51 and with an 
incidence of about 4 per 100 000 population per year,57 their inclusion in a revised clinical 
high risk state model may significantly increase the clinical ability to predict later psychotic 
recurrence. Indeed, early accounts confirmed the diagnostic instability, and change in 
ATPD/BPD is evident in about half of the patients,57 stressing that “brief psychotic episodes 
with an acute onset may be an early manifestation of schizophrenia”73 and that “should be 
studied as a potential risk group”.36  
 
To provide a clinical benchmark, as secondary outcome, we used a comparison group 
of remitted FES. We showed that brief psychotic episodes have a better long-term outcome 
than remitted FES after 24 months. The lower relapse risks were remarkable at ≥36 months, 
when the majority of FES subjects with previous remission had developed another psychotic 
episode, as compared with only half of those with an initial brief psychotic episode (defined 
as ATPD, BPD, BLIPS, and BIPS). Supplementary analyses of no significant differences at 6 
and 12 months may suggest a possible protective effect of antipsychotic medications on 
relapse (eFigure 2a), while there were no effects for the type of antipsychotic discontinuation 
(eFigure 2b) nor the criteria employed to define remission (eFigure 2c). Nevertheless, these 
findings should be interpreted cautiously, because this study was not primarily designed to 
test the impact of antipsychotic treatment on relapse prevention (for this see74-76). Overall, the 
reduced risk of psychotic recurrence among brief psychotic episodes is in line with earlier 
claims (in 199773) and later findings indicating an overall more favourable outcome in the 
domains of social disability, psychological impairment, and general functioning77 as 
compared with schizophrenia spectrum patients. Since our findings are robust and not 
affected by publication biases, they may serve as reliable predictive validators30 for the 
delineation of brief psychotic episodes from remitted schizophrenia (see eDiscussion  3). Data 
from this study could also be useful for future designation of early intervention programmes. 
For example, our risk estimates at different timepoints are clinically informative as healthcare 
professionals can inform patients and carers about their likely risks at a particular timepoint, 
since their index episode (see eDiscussion 4).  
 
There are some limitations to this study. Evidence of absence is not absence of 
evidence.78 However, our meta-analysis included a large dataset with up to 11133 patients 
where some statistical significant findings were yielded. Furthermore, we did not investigate 
outcomes other than psychotic recurrence. There is some evidence that a substantial 
proportion of ATPD patients may show non psychotic affective episodes during followup.77 
Also, we did not include affective psychoses as additional comparison group. For example, 
the relationship between brief psychotic episodes and bipolar affective disorders has been 
questioned.79 However, pilot literature searches did not uncover enough data for a quantitative 
meta-analysis of the two points above.  
 
CONCLUSIONS 
We found meta-analytical evidence for a better long-term prognosis of brief acute psychoses 
as compared with remitted schizophrenia, but no prognostic differences between ATPD, 
BPD, BLIPS and BIPS. Achieving diagnostic consensus across competing diagnostic 
constructs will greatly assist future attempts to identify the most effective ways to prevent 
psychotic recurrence after initial brief psychotic episodes.  
 
  
ACKNOWLEDGMENTS 
PFP had full access to all the data in the study and take responsibility for the integrity of the 
data and the accuracy of the data analysis. P.F.P.	  was	  supported	  in	  part	  by	  a	  2014	  NARSAD	  Young	  Investigator	  Award 
Study conception and design: PFP. 
Data analysis: PFP. 
Literature search and data extraction: MC GR and CH. 
Drafting of the manuscript: PFP. 
Revisions and editing: MC; GR, SB, IB, SL, CH, WC, and PMG.  
REFERENCES 
1.	   World	  Health	  Organization.	  International	  classification	  of	  diseases,	  tenth	  revision	  
(ICD-­‐10).	  Geneva:	  WHO,	  1990.	  1990.	  
2.	   Pillmann	  F,	  Marneros	  A.	  Brief	  and	  acute	  psychoses:	  the	  development	  of	  concepts.	  
Hist	  Psychiatry.	  Jun	  2003;14(54	  Pt	  2):161-­‐177.	  
3.	   Kahlbaum	  L.	  Die	  Gruppirung	  psychischer	  Krankheiten	  (Danzig).	  1863.	  
4.	   Kraepelin	  E.	  Psychiatrie.	  Ein	  Lehrbuch	  für	  Studirende	  und	  Aerzte.	  5.,	  vollständig	  
umgearbeitete	  Auflage.	  (Leipzig:	  Barth).	  1896.	  
5.	   Magnan	  VaL,	  M.	  Les	  Dégénérés.	  Etat	  mental	  et	  syndromes	  épisodiques.	  (Paris:	  
Rueff).	  1895.	  
6.	   Leonhard	  K.	  Die	  Aufteilung	  der	  endogenen	  Psychosen.	  1.	  Auflage	  (Berlin:	  Akademie-­‐
Verlag).	  1957.	  
7.	   Jaspers	  K.	  General	  Psychopathology.	  Chicago:	  University	  of	  Chicago	  Press;	  1963.	  
8.	   Störring	  GE,	  Suchenwirth	  R,	  Völkel	  H.	  Emotionalität	  und	  cycloide	  Psychosen.	  
Psychiatrie,	  Neurologie	  und	  Medizinische	  Psychologie.	  1962;14:85-­‐97.	  
9.	   Mitsuda	  H.	  The	  concept	  of	  "atypical	  psychoses"	  from	  the	  aspect	  of	  clinical	  genetics.	  
Acta	  Psychiatr	  Scand.	  1965;41(3):372-­‐377.	  
10.	   Langfeldt	  G.	  The	  schizophreniform	  states.	  Copenhagen:	  E.	  Munksgaard.	  1939.	  
11.	   American	  Psychiatric	  Association.	  Diagnostic	  and	  statistical	  manual	  of	  mental	  
disorders.	  5th	  ed.	  Washington,	  DC:	  American	  Psychiatric	  Association.	  2013.	  
12.	   Pillmann	  F,	  Marneros	  A.	  Longitudinal	  follow-­‐up	  in	  acute	  and	  transient	  psychotic	  
disorders	  and	  schizophrenia.	  Br	  J	  Psychiatry.	  Sep	  2005;187:286-­‐287.	  
13.	   Pillmann	  F,	  Haring	  A,	  Balzuweit	  S,	  Marneros	  A.	  A	  comparison	  of	  DSM-­‐IV	  brief	  
psychotic	  disorder	  with	  "positive"	  schizophrenia	  and	  healthy	  controls.	  Compr	  
Psychiatry.	  Sep-­‐Oct	  2002;43(5):385-­‐392.	  
14.	   Pillmann	  F,	  Haring	  A,	  Balzuweit	  S,	  Bloink	  R,	  Marneros	  A.	  The	  concordance	  of	  ICD-­‐10	  
acute	  and	  transient	  psychosis	  and	  DSM-­‐IV	  brief	  psychotic	  disorder.	  Psychol	  Med.	  Apr	  
2002;32(3):525-­‐533.	  
15.	   Castagnini	  A,	  Foldager	  L.	  Epidemiology,	  course	  and	  outcome	  of	  acute	  polymorphic	  
psychotic	  disorder:	  implications	  for	  ICD-­‐11.	  Psychopathology.	  2014;47(3):202-­‐206.	  
16.	   Fusar-­‐Poli	  P,	  Borgwardt	  S,	  Bechdolf	  A,	  et	  al.	  The	  Psychosis	  High-­‐Risk	  State	  A	  
Comprehensive	  State-­‐of-­‐the-­‐Art	  Review.	  Jama	  Psychiatry.	  Jan	  2013;70(1):107-­‐120.	  
17.	   Yung	  AR,	  Yuen	  HP,	  McGorry	  PD,	  et	  al.	  Mapping	  the	  onset	  of	  psychosis:	  the	  
Comprehensive	  Assessment	  of	  At-­‐Risk	  Mental	  States.	  Australian	  &	  New	  Zealand	  
Journal	  of	  Psychiatry.	  2005;39(11-­‐12):964-­‐971.	  
18.	   Yung	  AR,	  McGorry	  PD,	  McFarlane	  CA,	  et	  al.	  Monitoring	  and	  care	  of	  young	  people	  at	  
incipient	  risk	  of	  psychosis.	  Schizophr	  Bull.	  1996;22(2):283-­‐303.	  
19.	   Kistler	  JP,	  Ropper	  AA,	  Martin	  JB.	  Cerebrovascular	  diseases.	  In:	  Wilson	  JD,	  Braunwald	  
E,	  Isselbacher	  KJ,	  et	  al.,	  eds.	  Harrison's	  Principles	  of	  Internal	  Medicine.	  New	  York,	  NY:	  
McGraw-­‐Hill;	  1991:1977-­‐2002.	  
20.	   Wolf	  ME,	  Held	  VE,	  Hennerici	  MG.	  Risk	  scores	  for	  transient	  ischemic	  attack.	  Front	  
Neurol	  Neurosci.	  2014;33:41-­‐68.	  
21.	   Miller	  TJ,	  McGlashan	  TH,	  Rosen	  JL,	  et	  al.	  Prodromal	  assessment	  with	  the	  structured	  
interview	  for	  prodromal	  syndromes	  and	  the	  scale	  of	  prodromal	  symptoms:	  
predictive	  validity,	  interrater	  reliability,	  and	  training	  to	  reliability.	  Schizophrenia	  
Bulletin.	  2003;29(4):703-­‐715.	  
22.	   Fusar-­‐Poli	  P,	  Nelson	  B,	  Valmaggia	  L,	  Yung	  AR,	  McGuire	  PK.	  Comorbid	  depressive	  and	  
anxiety	  disorders	  in	  509	  individuals	  with	  an	  at-­‐risk	  mental	  state:	  impact	  on	  
psychopathology	  and	  transition	  to	  psychosis.	  Schizophr	  Bull.	  Jan	  2014;40(1):120-­‐131.	  
23.	   Schmidt	  SJ,	  Schultze-­‐Lutter	  F,	  Schimmelmann	  BG,	  et	  al.	  EPA	  guidance	  on	  the	  early	  
intervention	  in	  clinical	  high	  risk	  states	  of	  psychoses.	  Eur	  Psychiatry.	  Mar	  
2015;30(3):388-­‐404.	  
24.	   Winton-­‐Brown	  TT,	  Harvey	  SB,	  McGuire	  PK.	  The	  diagnostic	  significance	  of	  BLIPS	  (Brief	  
Limited	  Intermittent	  Psychotic	  Symptoms)	  in	  psychosis.	  Schizophr	  Res.	  Sep	  
2011;131(1-­‐3):256-­‐257.	  
25.	   Schultze-­‐Lutter	  F,	  Schimmelmann	  BG,	  Ruhrmann	  S.	  The	  near	  Babylonian	  speech	  
confusion	  in	  early	  detection	  of	  psychosis.	  Schizophr	  Bull.	  Jul	  2011;37(4):653-­‐655.	  
26.	   Zhang	  JP,	  Gallego	  JA,	  Robinson	  DG,	  et	  al.	  Efficacy	  and	  safety	  of	  individual	  second-­‐
generation	  vs.	  first-­‐generation	  antipsychotics	  in	  first-­‐episode	  psychosis:	  a	  systematic	  
review	  and	  meta-­‐analysis.	  Int	  J	  Neuropsychopharmacol.	  Jul	  2013;16(6):1205-­‐1218.	  
27.	   Fusar-­‐Poli	  P,	  Yung	  AR,	  McGorry	  P,	  van	  Os	  J.	  Lessons	  learned	  from	  the	  psychosis	  high-­‐
risk	  state:	  towards	  a	  general	  staging	  model	  of	  prodromal	  intervention.	  Psychol	  Med.	  
Jan	  2014;44(1):17-­‐24.	  
28.	   Stafford	  MR,	  Jackson	  H,	  Mayo-­‐Wilson	  E,	  Morrison	  AP,	  Kendall	  T.	  Early	  interventions	  
to	  prevent	  psychosis:	  systematic	  review	  and	  meta-­‐analysis.	  Bmj.	  2013;346:f185.	  
29.	   Kapur	  S,	  Phillips	  AG,	  Insel	  TR.	  Why	  has	  it	  taken	  so	  long	  for	  biological	  psychiatry	  to	  
develop	  clinical	  tests	  and	  what	  to	  do	  about	  it?	  Mol	  Psychiatry.	  Dec	  
2012;17(12):1174-­‐1179.	  
30.	   Kendell	  R,	  Jablensky	  A.	  Distinguishing	  between	  the	  validity	  and	  utility	  of	  psychiatric	  
diagnoses.	  Am	  J	  Psychiatry.	  Jan	  2003;160(1):4-­‐12.	  
31.	   Stroup	  DF,	  Berlin	  JA,	  Morton	  SC,	  et	  al.	  Meta-­‐analysis	  of	  observational	  studies	  in	  
epidemiology:	  a	  proposal	  for	  reporting.	  Meta-­‐analysis	  Of	  Observational	  Studies	  in	  
Epidemiology	  (MOOSE)	  group.	  Jama.	  Apr	  19	  2000;283(15):2008-­‐2012.	  
32.	   Yung	  AR,	  Phillips	  LJ,	  Yuen	  HP,	  McGorry	  PD.	  Comprehensive	  Assessment	  of	  at	  Risk	  
Mental	  State.	  Parkville	  Victoria,	  The	  PACE	  Clinic,	  ORYGEN	  Research	  Centre,	  
University	  of	  Melbourne,	  Department	  of	  Psychiatry;	  2006.	  
33.	   McGlashan	  TH,	  Walsh	  B,	  Wood	  SJ.	  The	  Psychosis-­‐Risk	  Syndrome.	  Handbook	  for	  
Diagnosis	  and	  Follow-­‐up.	  New	  York:	  Oxford	  University	  Press;	  2010.	  
34.	   Riecher-­‐Rossler	  A,	  Aston	  J,	  Ventura	  J,	  et	  al.	  The	  Basel	  screening	  instrument	  for	  
psychosis	  (BSIP):	  Development,	  structure,	  reliability	  and	  validity.	  Fortschritte	  Der	  
Neurologie	  Psychiatrie.	  Apr	  2008;76(4):207-­‐216.	  
35.	   Castagnini	  A,	  Berrios	  GE.	  Acute	  and	  transient	  psychotic	  disorders	  (ICD-­‐10	  F23):	  a	  
review	  from	  a	  European	  perspective.	  Eur	  Arch	  Psychiatry	  Clin	  Neurosci.	  Dec	  
2009;259(8):433-­‐443.	  
36.	   Correll	  CU,	  Smith	  CW,	  Auther	  AM,	  et	  al.	  Predictors	  of	  remission,	  schizophrenia,	  and	  
bipolar	  disorder	  in	  adolescents	  with	  brief	  psychotic	  disorder	  or	  psychotic	  disorder	  
not	  otherwise	  specified	  considered	  at	  very	  high	  risk	  for	  schizophrenia.	  J	  Child	  
Adolesc	  Psychopharmacol.	  Oct	  2008;18(5):475-­‐490.	  
37.	   Moher	  D,	  Liberati	  A,	  Tetzlaff	  J,	  Altman	  DG,	  Group	  P.	  Preferred	  reporting	  items	  for	  
systematic	  reviews	  and	  meta-­‐analyses:	  the	  PRISMA	  statement.	  BMJ.	  
2009;339:b2535.	  
38.	   Nyaga	  VN,	  Arbyn	  M,	  Aerts	  M.	  Metaprop:	  a	  Stata	  command	  to	  perform	  meta-­‐analysis	  
of	  binomial	  data.	  Arch	  Public	  Health.	  2014;72(1):39.	  
39.	   Newcombe	  RG.	  Two-­‐sided	  confidence	  intervals	  for	  the	  single	  proportion:	  
comparison	  of	  seven	  methods.	  Stat	  Med.	  Apr	  30	  1998;17(8):857-­‐872.	  
40.	   Freeman	  MF,	  Tukey	  JW.	  Transformations	  related	  to	  the	  angular	  and	  the	  square	  root.	  
Annals	  of	  Mathematical	  Statistics.	  1950;21:607-­‐611.	  
41.	   DerSimonian	  R,	  Laird	  N.	  Meta-­‐analysis	  in	  clinical	  trials.	  Control	  Clin	  Trials.	  Sep	  
1986;7(3):177-­‐188.	  
42.	   Lipsey	  M,	  Wilson	  D.	  Practical	  Meta-­‐analysis.	  Thousand	  Oaks,	  CA:	  Sage	  Publications;	  
2000.	  
43.	   Steichen	  T.	  Nonparametric	  trim	  and	  fill	  analysis	  of	  publication	  bias	  in	  meta-­‐analysis.	  .	  
Stata	  Technical	  Bulletin,	  StataCorp	  LP.	  2001:10-­‐57.	  
44.	   Peters	  JL,	  Sutton	  AJ,	  Jones	  DR,	  Abrams	  KR,	  Rushton	  L.	  Contour-­‐enhanced	  meta-­‐
analysis	  funnel	  plots	  help	  distinguish	  publication	  bias	  from	  other	  causes	  of	  
asymmetry.	  J	  Clin	  Epidemiol.	  Oct	  2008;61(10):991-­‐996.	  
45.	   Sterne	  JA,	  Egger	  M,	  Smith	  GD.	  Systematic	  reviews	  in	  health	  care:	  Investigating	  and	  
dealing	  with	  publication	  and	  other	  biases	  in	  meta-­‐analysis.	  BMJ.	  Jul	  14	  
2001;323(7304):101-­‐105.	  
46.	   Egger	  M,	  Davey	  Smith	  G,	  Schneider	  M,	  Minder	  C.	  Bias	  in	  meta-­‐analysis	  detected	  by	  a	  
simple,	  graphical	  test.	  BMJ.	  Sep	  13	  1997;315(7109):629-­‐634.	  
47.	   Harbord	  R,	  Harris	  R,	  Sterne	  A.	  Updated	  tests	  for	  small-­‐study	  effects	  in	  meta-­‐
analyses.	  2009;9(2):197-­‐210.	  
48.	   Marneros	  A,	  Pillmann	  P.	  Acute	  and	  transient	  psychoses.	  Cambridge:	  Cambridge	  
University	  Press;	  2004.	  
49.	   Moller	  HJ,	  Jager	  M,	  Riedel	  M,	  et	  al.	  The	  Munich	  15-­‐year	  follow-­‐up	  study	  
(MUFUSSAD)	  on	  first-­‐hospitalized	  patients	  with	  schizophrenic	  or	  affective	  disorders:	  
assessing	  courses,	  types	  and	  time	  stability	  of	  diagnostic	  classification.	  Eur	  Psychiatry.	  
May	  2011;26(4):231-­‐243.	  
50.	   Salvatore	  P,	  Baldessarini	  RJ,	  Tohen	  M,	  et	  al.	  McLean-­‐Harvard	  International	  First-­‐
Episode	  Project:	  two-­‐year	  stability	  of	  ICD-­‐10	  diagnoses	  in	  500	  first-­‐episode	  psychotic	  
disorder	  patients.	  J	  Clin	  Psychiatry.	  Feb	  2011;72(2):183-­‐193.	  
51.	   Heslin	  M,	  Lomas	  B,	  Lappin	  JM,	  et	  al.	  Diagnostic	  change	  10	  years	  after	  a	  first	  episode	  
of	  psychosis.	  Psychol	  Med.	  May	  4	  2015:1-­‐13.	  
52.	   Fusar-­‐Poli	  P,	  Van	  Os	  J.	  Lost	  in	  transition:	  setting	  psychosis	  trehsold	  in	  prodromal	  
research.	  Acta	  Psychiatr	  Scand.	  2013:in	  press.	  
53.	   McGlashan	  T,	  Walsh	  B,	  Woods	  S.	  The	  Psychosis-­‐Risk	  Syndrome:	  	  Handbook	  for	  
Diagnosis	  and	  Follow-­‐Up:	  Oxford	  Univ.	  Press;	  2010.	  
54.	   Fusar-­‐Poli	  P,	  Cappucciati	  M,	  Rutigliano	  G,	  et	  al.	  At	  risk	  or	  not	  at	  risk?	  Meta-­‐analysis	  
of	  the	  prognostic	  accuracy	  of	  psychometric	  interviews	  for	  psychosis	  prediction.	  
2015:in	  press.	  
55.	   Yung	  AR,	  Nelson	  B,	  Thompson	  A,	  Wood	  SJ.	  The	  psychosis	  threshold	  in	  Ultra	  High	  Risk	  
(prodromal)	  research:	  is	  it	  valid?	  Schizophr	  Res.	  Jul	  2010;120(1-­‐3):1-­‐6.	  
56.	   Kempton	  M,	  Bonoldi	  I,	  Valmaggia	  L,	  McGuire	  P,	  Fusar-­‐Poli	  P.	  Speed	  of	  psychosis	  
progression	  in	  people	  at	  ultra	  high	  clinical	  risk:	  a	  complementary	  meta-­‐analysis.	  
JAMA	  Psychiatry.	  2015.	  
57.	   Queirazza	  F,	  Semple	  DM,	  Lawrie	  SM.	  Transition	  to	  schizophrenia	  in	  acute	  and	  
transient	  psychotic	  disorders.	  Br	  J	  Psychiatry.	  2014;204:299-­‐305.	  
58.	   Miller	  TJ,	  McGlashan	  TH,	  Rosen	  JL,	  et	  al.	  Prodromal	  assessment	  with	  the	  structured	  
interview	  for	  prodromal	  syndromes	  and	  the	  scale	  of	  prodromal	  symptoms:	  
predictive	  validity,	  interrater	  reliability,	  and	  training	  to	  reliability.	  Schizophr	  Bull.	  
2003;29(4):703-­‐715.	  
59.	   Nelson	  B,	  Yuen	  K,	  Yung	  AR.	  Ultra	  high	  risk	  (UHR)	  for	  psychosis	  criteria:	  are	  there	  
different	  levels	  of	  risk	  for	  transition	  to	  psychosis?	  Schizophr	  Res.	  Jan	  2011;125(1):62-­‐
68.	  
60.	   Fusar-­‐Poli	  P,	  Byrne	  M,	  Badger	  S,	  Valmaggia	  LR,	  McGuire	  PK.	  Outreach	  and	  support	  in	  
south	  London	  (OASIS),	  2001-­‐2011:	  ten	  years	  of	  early	  diagnosis	  and	  treatment	  for	  
young	  individuals	  at	  high	  clinical	  risk	  for	  psychosis.	  Eur	  Psychiatry.	  Jun	  
2013;28(5):315-­‐326.	  
61.	   Fusar-­‐Poli	  P,	  Frascarelli	  M,	  Valmaggia	  L,	  et	  al.	  Antidepressant,	  antipsychotic	  and	  
psychological	  interventions	  in	  subjects	  at	  high	  clinical	  risk	  for	  psychosis:	  OASIS	  6-­‐
year	  naturalistic	  study.	  Psychol	  Med.	  Apr	  2015;45(6):1327-­‐1339.	  
62.	   Fusar-­‐Poli	  P,	  Cappucciati	  M,	  Borgwardt	  S,	  et	  al.	  Heterogeneity	  of	  risk	  for	  psychosis	  
within	  subjects	  at	  clinical	  high	  risk:	  meta-­‐analytical	  stratification	  JAMA	  Psychiatry.	  
2016:in	  press.	  
63.	   Mrazek	  P,	  Haggerty	  R.	  Reducing	  risks	  for	  mental	  disorders:	  Frontiers	  for	  preventive	  
intervention	  research.	  Washington:	  National	  Academy	  Press;	  1994.	  
64.	   Gordon	  RS,	  Jr.	  An	  operational	  classification	  of	  disease	  prevention.	  Public	  Health	  Rep.	  
Mar-­‐Apr	  1983;98(2):107-­‐109.	  
65.	   WHO.	  Prevention	  of	  Mental	  Disorders.	  Effective	  Interventions	  and	  Policy	  Options.	  
Geneva:	  Department	  of	  Mental	  Health	  and	  Substance	  Abuse;	  2004.	  
66.	   Fusar	  Poli	  P,	  Carpenter	  W,	  Wood	  S,	  McGlashan	  T.	  Attenuated	  Psychosis	  Syndrome:	  
ready	  for	  DSM-­‐5.1	  ?	  Annual	  Review	  of	  Clinical	  Psychology.	  2014;10(April	  2014):in	  
press.	  
67.	   Simon	  AE,	  Umbricht	  D,	  Lang	  UE,	  Borgwardt	  S.	  Declining	  transition	  rates	  to	  psychosis:	  
The	  role	  of	  diagnostic	  spectra	  and	  symptom	  overlaps	  in	  individuals	  with	  attenuated	  
psychosis	  syndrome.	  Schizophr	  Res.	  Nov	  2014;159(2-­‐3):292-­‐298.	  
68.	   Cornblatt	  BA,	  Carrion	  RE,	  Auther	  A,	  et	  al.	  Psychosis	  Prevention:	  A	  Modified	  Clinical	  
High	  Risk	  Perspective	  From	  the	  Recognition	  and	  Prevention	  (RAP)	  Program.	  Am	  J	  
Psychiatry.	  Jun	  5	  2015:appiajp201513121686.	  
69.	   McGorry	  PD.	  Early	  clinical	  phenotypes,	  clinical	  staging,	  and	  strategic	  biomarker	  
research:	  building	  blocks	  for	  personalized	  psychiatry.	  Biol	  Psychiatry.	  Sep	  15	  
2013;74(6):394-­‐395.	  
70.	   Mattila	  T,	  Koeter	  M,	  Wohlfarth	  T,	  et	  al.	  Impact	  of	  DSM-­‐5	  Changes	  on	  the	  Diagnosis	  
and	  Acute	  Treatment	  of	  Schizophrenia.	  Schizophr	  Bull.	  Dec	  20	  2014.	  
71.	   Heckers	  S,	  Barch	  DM,	  Bustillo	  J,	  et	  al.	  Structure	  of	  the	  psychotic	  disorders	  
classification	  in	  DSM-­‐5.	  Schizophr	  Res.	  Oct	  2013;150(1):11-­‐14.	  
72.	   Tandon	  R,	  Gaebel	  W,	  Barch	  DM,	  et	  al.	  Definition	  and	  description	  of	  schizophrenia	  in	  
the	  DSM-­‐5.	  Schizophr	  Res.	  Oct	  2013;150(1):3-­‐10.	  
73.	   Jorgensen	  P,	  Bennedsen	  B,	  Christensen	  J,	  Hyllested	  A.	  Acute	  and	  transient	  psychotic	  
disorder:	  a	  1-­‐year	  follow-­‐up	  study.	  Acta	  Psychiatr	  Scand.	  Aug	  1997;96(2):150-­‐154.	  
74.	   Kishimoto	  T,	  Agarwal	  V,	  Kishi	  T,	  et	  al.	  Relapse	  prevention	  in	  schizophrenia:	  a	  
systematic	  review	  and	  meta-­‐analysis	  of	  second-­‐generation	  antipsychotics	  versus	  
first-­‐generation	  antipsychotics.	  Mol	  Psychiatry.	  Jan	  2013;18(1):53-­‐66.	  
75.	   Leucht	  S,	  Barnes	  TR,	  Kissling	  W,	  et	  al.	  Relapse	  prevention	  in	  schizophrenia	  with	  new-­‐
generation	  antipsychotics:	  a	  systematic	  review	  and	  exploratory	  meta-­‐analysis	  of	  
randomized,	  controlled	  trials.	  Am	  J	  Psychiatry.	  Jul	  2003;160(7):1209-­‐1222.	  
76.	   Leucht	  S,	  Tardy	  M,	  Komossa	  K,	  et	  al.	  Antipsychotic	  drugs	  versus	  placebo	  for	  relapse	  
prevention	  in	  schizophrenia:	  a	  systematic	  review	  and	  meta-­‐analysis.	  Lancet.	  Jun	  2	  
2012;379(9831):2063-­‐2071.	  
77.	   Marneros	  A,	  Pillmann	  F,	  Haring	  A,	  Balzuweit	  S,	  Bloink	  R.	  What	  is	  schizophrenic	  in	  
acute	  and	  transient	  psychotic	  disorder?	  Schizophr	  Bull.	  2003;29(2):311-­‐323.	  
78.	   Altman	  DG,	  Bland	  JM.	  Absence	  of	  evidence	  is	  not	  evidence	  of	  absence.	  BMJ.	  Aug	  19	  
1995;311(7003):485.	  
79.	   Marneros	  A,	  Pillmann	  F,	  Haring	  A,	  Balzuweit	  S,	  Bloink	  R.	  The	  relation	  of	  "acute	  and	  
transient	  psychotic	  disorder"	  (ICD-­‐10	  F23)	  to	  bipolar	  schizoaffective	  disorder.	  J	  
Psychiatr	  Res.	  May-­‐Jun	  2002;36(3):165-­‐171.	  
Figure 1. Historical Genealogy of Current Competing Diagnostic Constructs for Brief Psychotic Episodes, Adapted from48  
 
Table 1. Competing Current Diagnostic Operationalizations for Brief Psychotic Episodes 
 CLINICAL HIGH RISK CLASSIFICATION FOR BRIEF 
PSYCHOTIC EPISODES 
STANDARD CLASSIFICATION FOR BRIEF PSYCHOTIC EPISODES 
Brief Intermittent Psychotic 
Symptom Prodromal 
Syndrome SIPS Version 5.033 
Brief Limited Intermittent 
Psychotic Symptoms Group 
CAARMS Version 12/200632 
Acute and Transient Psychotic 
Disorder 
ICD-10 Classification of Mental 
and Behavioural Disorders1 
Brief Psychotic Disorder 
DSM-5 Diagnostic and Statistical Manual of 
Mental Disorders11 
Symptoms At least one of the SOPS P1-P5 
Scales is scored 6 
	  
At least one of the CAARMS 
P1-P2-P4 Severity Scales is 
scored  6 or P3 is scored ≥ 5 	  
Delusions, hallucinations, 
incomprehensible or incoherent 
speech, or any combination of these 
 
At least one of the following symptoms. At 
least one of these must be (1), (2), or (3): 
1. Delusions 
2. Hallucinations 
3. Disorganized speech (e.g., frequent 
derailment or incoherence) 
4. Grossly disorganized or catatonic behaviour 
Onset Symptoms should have reached 
a psychotic level of intensity in 
the previous 3 mo	  
Symptoms should have been 
present  in the previous 12 mo 
and for not longer than 5 y	  
Symptoms should have an acute 
onset, i.e. the time interval between 
the first appearance of any psychotic 
symptoms and the presentation of the 
fully developed disorder should not 
exceed 2 wk 
Symptoms should have a sudden onset, i.e. a 
change from a non-psychotic state to a clearly 
psychotic state within 2 wk, usually without a 
prodrome 
Duration and 
frequency  
 
Up to 3 mo, at a frequency of  at 
least several min per d at least 
once per mo but less than  one h 
per d for 4 d per wk in the past 
mo 
 
Up to 7 d, 	  at a frequency of at 
least 3–4 times a wk when 
lasting at least 1 h or at least a 
daily presence when lasting 
less than 1 h 
 
F23.0 Acute polymorphic psychotic 
disorder without symptoms of 
schizophrenia: Up to 3 mo, for at 
least several h 
F23.1 Acute polymorphic psychotic 
disorder with symptoms of 
schizophrenia: Up to 1 mo, for the 
majority of time 
F23.2 Acute schizophrenia-like 
psychotic disorder:  Up to 1 mo, for 
the majority of time 
F23.3 Other acute predominantly 
delusional psychotic disorder: Up to 
3 mo, for the majority of time   
At least 1 d, up to 1 mo 
 
Level of 
functioning 
No social/occupational 
dysfunction requirement 	  
30% drop in SOFAS score 
from premorbid level, sustained 
for a mo, within past 12 mo or 
SOFAS score<50 for past 12 
mo or more 
No social/occupational dysfunction 
requirement 
No social/occupational dysfunction 
requirement 
Exclusion 
criteria 
 
Symptoms are seriously 
disorganizing and dangerous 
- 
 
- 
 
- 
 
Symptoms are strongly 
intertwined temporally with 
substance use episodes 
(substance-induced psychosis 
may be considered) 
 
 
 
 
 
 
 
 
Symptoms occur only during 
peak intoxication from a 
substance known to be 
associated with psychotic 
experiences (e.g. 
hallucinogens, amphetamines, 
cocaine) 
 
 
 
 
 
 
 
Evidence of recent psychoactive 
substance use sufficient to fulfil the 
criteria of intoxication (F1x.0), 
harmful use, (F1x.1), dependence 
(F1x.2) or withdrawal states (F1x.3 
and F1x.4). Presence of organic brain 
disease (F0) or serious metabolic 
disturbances affecting the central 
nervous system (this does not include 
childbirth). Perplexity, 
misidentification, or impairment of 
attention and concentration fulfil the 
criteria for Delirium, not induced by 
alcohol and other psychoactive 
substances (F05-A) 
Symptoms are due to the direct physiological 
effects of a substance (e.g., a drug of abuse, a 
medication) or to a general medical condition 
 
 
 
 
 
 
 
 
 
 
 
Symptoms are better accounted 
for by another DSM diagnosis  
 
- 
 
 
Symptoms meet diagnostic criteria 
for manic episode (F30), depressive 
episode (F32), or recurrent depressive 
disorder (F33) 
Symptoms are better explained by major 
depressive or bipolar disorder with psychotic 
features  
 
Past psychosis ruled in 
according to information 
obtained through the initial 
screen and evaluated using the 
POPS  
The person has had a previous 
psychotic episode (treated or 
untreated) 
 
 Symptoms are better explained by another 
psychotic disorder such as schizophrenia or 
catatonia 
 
- 
 
Symptoms do not resolve 
spontaneously* (*without 
antipsychotic medication) 
- - 
CAARMS, Comprehensive Assessment of At Risk Mental State; d, day; GAF, Global Assessment of Functioning; h, hour; ICD-10, The International Classification of Diseases; 
DSM (-V), Diagnostic and Statistical Manual of Mental Disorders; min, minute; mo, month; POPS, Presence of Psychotic Symptoms criteria; SIPS, Structured Interview for 
Prodromal Syndromes; SOFAS, Social and Occupational Functioning Assessment Scale; wk, week. 
Figure 2. Meta-analytical Prognosis of Brief Psychotic Episodes over Follow-up Time. * p<0.05, ** p<0.001.  
 
Table 2 to Figure 2   
  Follow-up  
  6 months 12 months 24 months ≥36 months 
Samples (n) 25 46 35 42 
Subjects (n) 1311 1833 1669 11133 
BLIPS (mean,95%CI) 0.08 0.00 0.23 0.28 0.08 0.52 0.32 0.11 0.57 0.30 0.12 0.52 
BIPS (mean, 95%CI) 0.22 0.09 0.36 0.35 0.23 0.48 0.43 0.26 0.61 0.46 0.32 0.61 
ATPD (mean, 95%CI) 0.13 0.09 0.18 0.30 0.19 0.42 0.38 0.27 0.48 0.54 0.41 0.66 
BPD (mean, 95%CI) 0.20 0.08 0.36 0.31 0.12 0.52 0.46 0.31 0.60 0.53 0.34 0.72 
FES (mean, 95%CI) 0.30 0.15 0.48 0.42 0.30 0.54 0.78 0.58 0.93 0.84 0.70 0.94 
BLIPS vs BIPS vs ATPD vs BPD Test for 
between group heterogeneity (Q, p) 
4.71 0.19 0.90 0.83 1.20 0.75 3.65 0.30 
BLIPS vs BIPS vs ATPD vs BPD vs FES 
Test for between group heterogeneity (Q, p) 
7.63 0.11 2.36 0.67 11.97 0.02 16.97 <0.001 
BLIPS, Brief and Limited Intermittent Psychotic Symptoms; BIPS, Brief Intermittent Psychotic Symptoms; ATPD, Acute and Transient 
Psychotic Episode; BPD, Brief Psychotic Disorder; Overall risk of psychotic recurrence across BLIPS, BIPS, ATPD, BPD combined 
together: 6 months 0.12 (95% CI 0.07-0.17), 12 months 0.30 (95% CI 0.22-0.39), 24 months 0.39 (95% CI 0.32-0.47), 36 months 0.51 
(95% CI 0.41-0.61); BLPS n=168, BIPS n=125, BPD n=308, ATPD n=10645, FES n=1201. The index episode is defined at the 
remission of the first episode of BLIPS, BIPS, ATPD, BPD, and FES. Details on the definition of the index episode are appended in 
eDiscussion 4. 
 
